932
Views
8
CrossRef citations to date
0
Altmetric
Author's View

The ELR+CXCL chemokines and their receptors CXCR1/CXCR2

A signaling axis and new target for the treatment of renal cell carcinoma

, , &
Article: e28399 | Received 20 Feb 2014, Accepted 01 Mar 2014, Published online: 09 Apr 2014

References

  • Eisen T, Sternberg CN, Robert C, Mulders P, Pyle L, Zbinden S, Izzedine H, Escudier B. Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst 2012; 104:93 - 113; http://dx.doi.org/10.1093/jnci/djr511; PMID: 22235142
  • Escudier B. Sunitinib for the management of advanced renal cell carcinoma. Expert Rev Anticancer Ther 2010; 10:305 - 17; http://dx.doi.org/10.1586/era.10.26; PMID: 20214511
  • Sparmann A, Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004; 6:447 - 58; http://dx.doi.org/10.1016/j.ccr.2004.09.028; PMID: 15542429
  • Grepin R, Guyot M, Jacquin M, Durivault J, Chamorey E, Sudaka A, Serdjebi C, Lacarelle B, Scoazec JY, Negrier S, et al. Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines. Oncogene 2012; 31:1683 - 94; http://dx.doi.org/10.1038/onc.2011.360; PMID: 21909141
  • Grépin R, Guyot M, Giuliano S, Boncompagni M, Ambrosetti D, Chamorey E, Scoazec JY, Negrier S, Simonnet H, Pagès G. The CXCL7/CXCR1/2 axis is a key driver in the growth of clear cell renal cell carcinoma. Cancer Res 2014; 74:873 - 83; http://dx.doi.org/10.1158/0008-5472.CAN-13-1267; PMID: 24335961
  • Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005; 65:671 - 80; PMID: 15705858
  • Levashova ZB, Sharma N, Timofeeva OA, Dome JS, Perantoni AO. ELR+-CXC chemokines and their receptors in early metanephric development. J Am Soc Nephrol 2007;; 18:2359 - 70; http://dx.doi.org/10.1681/ASN.2006040380; PMID: 17634442
  • Ginestier C, Liu S, Diebel ME, Korkaya H, Luo M, Brown M, Wicinski J, Cabaud O, Charafe-Jauffret E, Birnbaum D, et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 2010; 120:485 - 97; http://dx.doi.org/10.1172/JCI39397; PMID: 20051626
  • Liu S, Ginestier C, Ou SJ, Clouthier SG, Patel SH, Monville F, Korkaya H, Heath A, Dutcher J, Kleer CG, et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res 2011; 71:614 - 24; http://dx.doi.org/10.1158/0008-5472.CAN-10-0538; PMID: 21224357
  • Acosta JC, Gil J. A role for CXCR2 in senescence, but what about in cancer?. Cancer Res 2009; 69:2167 - 70; http://dx.doi.org/10.1158/0008-5472.CAN-08-3772; PMID: 19276354

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.